申联生物医药(上海)股份有限公司关于持股5%以上股东权益变动触及1%刻度及减持计划完成暨减持股份结果公告

Core Viewpoint - United Biomedical, Inc. (UBI) has completed its share reduction plan, decreasing its stake in Shenglian Biomedical (Shanghai) Co., Ltd. from 10.52% to 7.52% through the sale of 12,319,240 shares, which constitutes 3.00% of the company's total share capital [1][2][3]. Shareholder Holding Situation - Before the reduction plan, UBI held 43,199,898 shares, representing 10.52% of the total share capital of Shenglian Biomedical [1]. - The shares were acquired prior to the company's initial public offering and have been tradable since October 28, 2020 [1]. Implementation Results of the Reduction Plan - UBI's reduction plan was disclosed on October 23, 2025, with a maximum intended reduction of 12,319,320 shares [2]. - As of February 9, 2026, UBI successfully reduced its holdings by 12,319,240 shares, achieving the planned reduction [2]. Changes in Equity - Following the reduction, UBI's total shareholding decreased from 33,960,458 shares to 30,880,658 shares, with the ownership percentage dropping from 8.27% to 7.52% [3][4]. - This change in equity does not trigger a mandatory tender offer and will not affect the company's controlling shareholder or actual controller [3][4]. Other Notes - The reduction was executed in compliance with previously disclosed plans and does not involve any changes to the company's governance structure or ongoing operations [4][5]. - UBI has no concerted actions with other parties regarding this shareholding change [3].